101.25 -5.52 (-5.17%)
Pre-Market: 8:27AM EST
|Bid||101.11 x 3000|
|Ask||102.50 x 1100|
|Day's Range||102.30 - 110.95|
|52 Week Range||20.10 - 300.00|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||140.00|
The company reported revenues of $28.3 million during the third quarter of 2018 as compared to Wall Street analyst estimates of $26.6 million (or 35.1 million Canadian dollars) during the quarter. The below chart compares revenues for Trulieve since the third quarter of 2017. The Horizons Marijuana Life Sciences Index ETF (HMMJ) holds 11.8% of its total investments in Tilray (TLRY), 0.5% in WeedMD (WMD) (WDDMF), and 1.0% in Vivo Cannabis (VVCIF).
MedMen Enterprises (MMNFF) holds 19 licensed cannabis facilities for cultivation, manufacturing, and marketing cannabis as a consumer product. This article compares MedMen’s (MMNFF) valuation with its peers’, including Tilray (TLRY), CannaRoyalty (OH), and Maricann (MRRCF).
The cannabis sector ended in negative territory last week. The Horizons Marijuana Life Sciences ETF (HMMJ) fell ~6.2%, and the ETFMG Alternative Harvest ETF (MJ) fell 5.8% during the period. Most cannabis stocks also ended in the negative territory.
MedMen (MMNFF) has entered into agreements with different companies to expand its footprint. We outline a few of the recent agreements below.
/ This month marijuana stocks have been very active. As of November 7, US Attorney General Jeff Sessions is out and an interim AG is in. This all occurred following Canada’s full legalization of recreational and medicinal cannabis.
The good news is — if you’re an investor that desires price volatility working for you rather than against you — Under Armour (NYSE:UAA), Chipotle (NYSE:CMG) and Tilray (NASDAQ:TLRY) are bear-busting stocks to buy today. Toss in decent, but not over-the-top short interest to help fuel the upside and the peace of mind that comes with owning brand recognition and a large-cap company—and the case for UAA, CMG and TLRY only grows stronger. Click to Enlarge The first of our large-cap stocks to buy is Under Armour.
Trulieve Cannabis Corp (TCNNF) is a licensed medical cannabis company set to release its Q3 2018 earnings on November 19 at 10:00 AM ET. Analysts expect Trulieve to report revenues of 35.1 million Canadian dollars for the third quarter of 2018. Trulieve is a vertically integrated cannabis company involved in the cultivation, production, and commercialization of cannabis products in the State of Florida.
Cannabis stocks have made several investors wary because of their high level of volatility. Earlier this week, some of the companies that reported earnings such as Canopy Growth (WEED), Tilray (TLRY), and Aurora Cannabis (ACB) (ACBFF) missed analysts’ estimates by a large margin, and the stocks got hammered. In an interview with CNBC, Andrew Left of Citron Research was largely pessimistic on the Canadian cannabis industry and expects that cannabis stocks will fall in the near term.
On November 15, the widely followed host of Mad Money on CNBC, Jim Cramer, gave his opinions on the cannabis industry. Cramer pointed investors to Canopy Growth (WEED) (CGC), the Canadian cannabis (HMMJ) giant, because of its backing from Constellation Brands as a result of the latter’s $4 billion investment.
There was a flurry of earnings releases this week from leaders of the Canadian cannabis industry. Here are the winners and losers.
The big financial institutions are negative right now and that means any positive light is going to be bent into negative light, Jim Cramer told his Mad Money viewers on Thursday evening. Right now, all the talk is about "late cycle," as in, we're in the late stage of the economic cycle. The economy can handle the initial rate hikes from the Federal Reserve, because rates were so low to begin with, Cramer reasoned.
is still a buy, according to analysts at Cowen, who lowered the company's price target to $150 a share from $172, while maintaining their "outperform" rating. Shares of Tilray were rising about 6% on Thursday. Tilray was part of a spate of cannabis company earnings releases this week, reporting revenue of $10 million that was slightly below estimates, which sent the stock tumbling following the release.
Canada’s pot industry reported its latest financial results this week, and investors think the September quarter was a bust. The U.S.-listed stocks of Canadian producers (WEED) (ticker: CGC), (ACB) (ACB), and (TLRY) (TLRY) are sinking. Since Monday, when Aurora reported a 333% sales jump from its year-ago quarter, its New York Stock Exchange–listed stock has slipped 18%, to US$6.16.
The global legal marijuana market is expected to reach USD 146.4 billion by end of 2025, according to a new report by Grand View Research, Inc. Growing adoption of marijuana in several medical applications such as cancer, mental disorders, chronic pain, and others is expected to propel revenue growth in the near future. As the industry continues to gain the attention of early investors, companies like Premier Health Group, Inc. (PHGRF) (PHGI), Aurora Cannabis (ACB)(ACB), New Age Beverages (NBEV), and Tilray (TLRY) are working toward new sector growth. Premier Health Group, Inc. (PHGRF) (PHGI) is focused on developing innovative approaches that combine human skill-based expertise with emerging technologies for the healthcare industry.
Underlying Shopify stock is an attractive, and fast-growing business. Indeed, I’ve laid out the bull case for SHOP in the past. After explosive gains from an IPO price of just $17, Shopify stock has settled into a wide range from $120 to $170 over the past ten months.
During the second quarter, Canopy Growth’s (WEED) (CGC) operating losses widened from ~$1 million to almost $214 million. The company reported a net loss of $330 million, which widened from losses of $1.6 million a year ago in 2017.